{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:59:04Z","timestamp":1793897944594,"version":"4.8.0"},"reference-count":92,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Over the past several decades, viral vector-based vaccines have emerged as some of the most versatile and potent platforms in modern vaccinology. Their capacity to deliver genetic material encoding target antigens directly into host cells enables strong cellular and humoral immune responses, often superior to what traditional inactivated or subunit vaccines can achieve. This has accelerated their application to a wide array of pathogens and disease targets, from well-established threats like HIV and malaria to emerging infections such as Ebola, Zika, and SARS-CoV-2. The COVID-19 pandemic further highlighted the agility of viral vector platforms, with several adenovirus-based vaccines quickly authorized and deployed on a global scale. Despite these advances, significant challenges remain. One major hurdle is pre-existing immunity against commonly used vector backbones, which can blunt vaccine immunogenicity. Rare but serious adverse events, including vector-associated inflammatory responses and conditions like vaccine-induced immune thrombotic thrombocytopenia (VITT), have raised important safety considerations. Additionally, scaling up manufacturing, ensuring consistency in large-scale production, meeting rigorous regulatory standards, and maintaining equitable global access to these vaccines present profound logistical and ethical dilemmas. In response to these challenges, the field is evolving rapidly. Sophisticated engineering strategies, such as integrase-defective lentiviral vectors, insect-specific flaviviruses, chimeric capsids to evade neutralizing antibodies, and plug-and-play self-amplifying RNA approaches, seek to bolster safety, enhance immunogenicity, circumvent pre-existing immunity, and streamline production. Lessons learned from the COVID-19 pandemic and prior outbreaks are guiding the development of platform-based approaches designed for rapid deployment during future public health emergencies. This review provides an exhaustive, in-depth examination of the historical evolution, immunobiological principles, current platforms, manufacturing complexities, regulatory frameworks, known safety issues, and future directions for viral vector-based vaccines.<\/jats:p>","DOI":"10.3390\/vaccines13050524","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:39:16Z","timestamp":1747283956000},"page":"524","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Justin","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Biomedical Science, University of Guelph, Guelph, ON N1G 2W1, Canada"},{"name":"Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Al","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian L.","family":"Campian","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Andrei, G. (2021). Vaccines and Antivirals: Grand Challenges and Great Opportunities. Specialty Grand Challenge article. Front. Virol., 23.","DOI":"10.3389\/fviro.2021.666548"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1007\/s13346-023-01362-3","article-title":"Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy","volume":"13","author":"Dogbey","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in Viral Vector-Based Vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Deng, S., Liang, H., Chen, P., Li, Y., Li, Z., Fan, S., Wu, K., Li, X., Chen, W., and Qin, Y. (2022). Viral Vector Vaccine Development and Application during the COVID-19 Pandemic. Microorganisms, 10.","DOI":"10.3390\/microorganisms10071450"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Silver, S. (1986). A Modern Approach to Live Vaccines: Recombinant Poxviruses. Biotechnology: Potentials and Limitations. Dahlem Workshop Reports, Springer.","DOI":"10.1007\/978-3-642-70535-9"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kaynarcalidan, O., Moreno Mascaraque, S., and Drexler, I. (2021). Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121780"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mahesh, S., Li, J., Travieso, T., Psaradelli, D., Negri, D., Klotman, M., Cara, A., and Blasi, M. (2023). Integrase Defective Lentiviral Vector Promoter Impacts Transgene Expression in Target Cells and Magnitude of Vector-Induced Immune Responses. Viruses, 15.","DOI":"10.3390\/v15112255"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Salauddin, M., Saha, S., Hossain, M.G., Okuda, K., and Shimada, M. (2024). Clinical Application of Adenovirus (AdV): A Comprehensive Review. Viruses, 16.","DOI":"10.3390\/v16071094"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.4049\/jimmunol.172.10.6290","article-title":"Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity","volume":"172","author":"Barouch","year":"2004","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: Humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Kobinger","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Coughlan, L. (2020). Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00909"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102210","DOI":"10.1016\/j.coi.2022.102210","article-title":"Viral vector vaccines","volume":"77","author":"McCann","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wang, W.C., Sayedahmed, E.E., and Mittal, S.K. (2022). Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy. Viruses, 14.","DOI":"10.3390\/v14122727"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-Mediated Gene Therapy for Research and Therapeutic Purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu. Rev. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Weber, T. (2021). Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.658399"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Calcedo, R., and Wilson, J.M. (2013). Humoral Immune Response to AAV. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00341"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-031-27681-1_18","article-title":"Preexisting Neutralizing Antibodies against Different Adeno-Associated Virus Serotypes in Humans and Large Animal Models for Gene Therapy","volume":"1415","author":"Ail","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of Modified Vaccinia virus Ankara vaccines","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hannas, Z.T.J., Zhang, Y., Lhermitte, F., Cleuziat, C., Motes-Kreimeyer l Dhoms, P., and Bublot, M. (2020). Manufacturing and Control of Viral Vectored Vaccines: Challenges, Springer.","DOI":"10.1007\/978-3-030-51927-8_12"},{"key":"ref_24","first-page":"2157","article-title":"Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections","volume":"S1","author":"Marzi","year":"2011","journal-title":"J. Bioterror. Biodef."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz-Al\u00eda, M.\u00c1., Nace, R.A., Balakrishnan, B., Zhang, L., Packiriswamy, N., Singh, G., Warang, P., Mena, I., Narjari, R., and Vandergaast, R. (2024). Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity. mBio, 15.","DOI":"10.1128\/mbio.02928-23"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Tcheou, J., Raskin, A., Singh, G., Kawabata, H., Bielak, D., Sun, W., Gonz\u00e1lez-Dom\u00ednguez, I., Sather, D.N., Garc\u00eda-Sastre, A., and Palese, P. (2021). Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.791764"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nm.4253","article-title":"A chikungunya fever vaccine utilizing an insect-specific virus platform","volume":"23","author":"Erasmus","year":"2017","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tan, L., Zhang, Y., Kim, D.Y., and Li, R. (2023). Insect-Specific Chimeric Viruses Potentiated Antiviral Responses and Inhibited Pathogenic Alphavirus Growth in Mosquito Cells. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.03613-22"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/intimm\/dxp017","article-title":"The roles of TLRs, RLRs and NLRs in pathogen recognition","volume":"21","author":"Kawai","year":"2009","journal-title":"Int. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12985-024-02503-x","article-title":"The RNA-binding proteins regulate innate antiviral immune signaling by modulating pattern recognition receptors","volume":"21","author":"Li","year":"2024","journal-title":"Virol. J."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Panagioti, E., Klenerman, P., Lee, L.N., van der Burg, S.H., and Arens, R. (2018). Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00276"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Nemirov, K., Bourgine, M., Anna, F., Wei, Y., Charneau, P., and Majlessi, L. (2023). Lentiviral Vectors as a Vaccine Platform against Infectious Diseases. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030846"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-1-60761-533-0_6","article-title":"Integrase defective, nonintegrating lentiviral vectors","volume":"614","author":"Michelini","year":"2010","journal-title":"Methods Mol Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1016\/j.jcyt.2024.04.040","article-title":"Transformative advances in lentiviral vector manufacturing: Unlocking efficiency and cost-effectiveness with Tet-Off PCL innovation","volume":"26","author":"Ravari","year":"2024","journal-title":"Cytotherapy"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Porier, D.L., Adam, A., Kang, L., Michalak, P., Tupik, J., Santos, M.A., Tanelus, M., L\u00f3pez, K., Auguste, D.I., and Lee, C. (2024). Humoral and T-cell-mediated responses to an insect-specific flavivirus-based Zika virus vaccine candidate. PLoS Pathog., 20.","DOI":"10.1371\/journal.ppat.1012566"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6883","DOI":"10.4049\/jimmunol.0901466","article-title":"What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?","volume":"183","author":"Belyakov","year":"2009","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s13346-021-01001-9","article-title":"Mucosal and transdermal vaccine delivery strategies against COVID-19","volume":"12","author":"Kumar","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1001\/jama.2017.15033","article-title":"The Critical Role of Biomedical Research in Pandemic Preparedness","volume":"318","author":"Marston","year":"2017","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1473-3099(19)30266-X","article-title":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial","volume":"19","author":"Modjarrad","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/infdis\/jiq114","article-title":"An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: Results from a randomized placebo-controlled trial (the Step study)","volume":"203","author":"Fitzgerald","year":"2011","journal-title":"J. Infect Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI60988","article-title":"Rare serotype adenoviral vectors for HIV vaccine development","volume":"122","author":"Michael","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ondondo, B.O. (2014). The influence of delivery vectors on HIV vaccine efficacy. Front. Microbiol., 5.","DOI":"10.3389\/fmicb.2014.00439"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Shoukry, N.H. (2018). Hepatitis C Vaccines, Antibodies, and T Cells. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01480"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e0116624","DOI":"10.1128\/jvi.01166-24","article-title":"Headless hemagglutinin-containing influenza viral particles direct immune responses toward more conserved epitopes","volume":"98","author":"Hamele","year":"2024","journal-title":"J. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e0067423","DOI":"10.1128\/jvi.00674-23","article-title":"Adenoviral-vectored universal influenza vaccines administered intranasally reduce lung inflammatory responses upon viral challenge 15 months post-vaccination","volume":"97","author":"Misplon","year":"2023","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Flaxman, A., Sebastian, S., Appelberg, S., Cha, K.M., Ulaszewska, M., Purushotham, J., Gilbride, C., Sharpe, H., Spencer, A.J., and Bibi, S. (2024). Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse. PLoS Pathog., 20.","DOI":"10.1371\/journal.ppat.1012262"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/1078-0432.CCR-23-3940","article-title":"Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses","volume":"30","author":"Leoni","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e000928","DOI":"10.1136\/jitc-2020-000928","article-title":"Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: A phase I clinical trial","volume":"8","author":"Cappuccini","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e25793","DOI":"10.1002\/jia2.25793","article-title":"Current approaches to HIV vaccine development: A narrative review","volume":"24","author":"Kim","year":"2021","journal-title":"J. Int. AIDS Soc."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1093\/infdis\/jiae113","article-title":"HIV Diagnostics and Vaccines: It Takes Two to Tango","volume":"229","author":"Hural","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/S2352-3018(23)00264-3","article-title":"Prophylactic HIV-1 vaccine trials: Past, present, and future","volume":"11","author":"Nkolola","year":"2024","journal-title":"Lancet HIV."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10238-024-01436-7","article-title":"Personalized neoantigen cancer vaccines: Current progression, challenges and a bright future","volume":"24","author":"Wu","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Wei Xie, P.G. (2022, January 11\u201314). From discovary to Production: Challenges and Novel Methodologies for Next Generation Biomanufacturing. Proceedings of the 2022 Winter Simulation Conference (WSC), Singapore.","DOI":"10.1109\/WSC57314.2022.10015464"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13568-019-0794-5","article-title":"Large-scale microcarrier culture of HEK293T cells and Vero cells in single-use bioreactors","volume":"9","author":"Yang","year":"2019","journal-title":"AMB Express."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41421-022-00517-9","article-title":"Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2","volume":"9","author":"Ai","year":"2023","journal-title":"Cell Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1016\/S1473-3099(23)00126-3","article-title":"RTS,S\/AS01 malaria vaccine-proven safe and effective?","volume":"23","author":"Benn","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40259-023-00623-4","article-title":"Good MF. Malaria Vaccines: Progress to Date","volume":"37","author":"Stanisic","year":"2023","journal-title":"BioDrugs"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e0162723","DOI":"10.1128\/jvi.01627-23","article-title":"Translational success of fundamental virology: A VSV-vectored Ebola vaccine","volume":"98","author":"Anderson","year":"2024","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12936-020-03253-1","article-title":"The thermostability of the RTS,S\/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01","volume":"19","author":"Fortpied","year":"2020","journal-title":"Malar. J."},{"key":"ref_61","unstructured":"US Food and Drug Administration (2020). Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-Up: Guidance for Industry, US Food and Drug Administration."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Tang, J. (2025). Using UV\u2013Vis Titration to Elucidate Novel Epigallocatechin Gallate (EGCG)-Induced Binding of the c-MYC G-Quadruplex. Pharmaceuticals, 18.","DOI":"10.3390\/ph18050719"},{"key":"ref_63","unstructured":"US Food and Drug Administration (1997). International Regulatory Harmonization FDA Guidance Documents, US Food and Drug Administration."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Tang, J., Amin, M.A., and Campian, J.L. (2025). Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance. Cells, 14.","DOI":"10.20944\/preprints202503.1215.v1"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Coutant, F., Frenkiel, M.P., Despres, P., and Charneau, P. (2008). Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003973"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Tang, J., Karbhari, N., and Campian, J.L. (2025). Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions. Cells, 14.","DOI":"10.20944\/preprints202502.1189.v1"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s12250-020-00250-1","article-title":"Freeze-Drying Formulations Increased the Adenovirus and Poxvirus Vaccine Storage Times and Antigen Stabilities","volume":"36","author":"Chen","year":"2021","journal-title":"Virol. Sin."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Pastorino, B., Baronti, C., Gould, E.A., Charrel, R.N., and de Lamballerie, X. (2015). Effect of chemical stabilizers on the thermostability and infectivity of a representative panel of freeze dried viruses. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118963"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-3-031-34567-8_14","article-title":"International Harmonization for Cell and Gene Therapy Products","volume":"1430","author":"Arcidiacono","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/00185787221130703","article-title":"RxLegal: Emergency Use Authorizations","volume":"58","author":"Gabay","year":"2023","journal-title":"Hosp. Pharm."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Gurumoorthy, N., Nordin, F., Tye, G.J., Wan Kamarul Zaman, W.S., and Ng, M.H. (2022). Non-Integrating Lentiviral Vectors in Clinical Applications: A Glance Through. Biomedicines, 10.","DOI":"10.3390\/biomedicines10010107"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Dicks, M.D., Spencer, A.J., Edwards, N.J., Wadell, G., Bojang, K., Gilbert, S.C., Hill, A.V., and Cottingham, M.G. (2012). A novel chimpanzee adenovirus vector with low human seroprevalence: Improved systems for vector derivation and comparative immunogenicity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040385"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e001046","DOI":"10.1136\/jitc-2020-001046","article-title":"Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity","volume":"8","author":"Singh","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood.2022017696","article-title":"Vaccine-induced immune thrombotic thrombocytopenia","volume":"141","author":"Cines","year":"2023","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"npj Vaccines"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(21)00306-9","article-title":"Vaccine-induced immune thrombotic thrombocytopenia","volume":"9","author":"Klok","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3390\/idr14040057","article-title":"Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review","volume":"14","author":"Garg","year":"2022","journal-title":"Infect Dis. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e0083224","DOI":"10.1128\/jvi.00832-24","article-title":"A temperature-sensitive and less immunogenic Sendai virus for efficient gene editing","volume":"98","author":"Stevens","year":"2024","journal-title":"J. Virol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Fu, H., Liang, Y., Zhong, X., Pan, Z., Huang, L., Zhang, H., Xu, Y., Zhou, W., and Liu, Z. (2020). Codon optimization with deep learning to enhance protein expression. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-74091-z"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Tenbusch, M., Kuate, S., Tippler, B., Gerlach, N., Schimmer, S., Dittmer, U., and \u00dcberla, K. (2008). Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity. BMC Immunol., 9.","DOI":"10.1186\/1471-2172-9-13"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41541-024-01017-5","article-title":"A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccines","volume":"9","author":"Ho","year":"2024","journal-title":"npj Vaccines"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1126\/science.abb8923","article-title":"Rapid COVID-19 vaccine development","volume":"368","author":"Graham","year":"2020","journal-title":"Science"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment","volume":"397","author":"Wouters","year":"2021","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e013669","DOI":"10.1136\/bmjgh-2023-013669","article-title":"Designing the global vaccine supply chain: Balancing intellectual property rights with post COVID-19 vaccine equity","volume":"8","author":"Park","year":"2023","journal-title":"BMJ Glob. Health"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1016\/j.vaccine.2015.04.036","article-title":"Vaccine hesitancy: Definition, scope and determinants","volume":"33","author":"MacDonald","year":"2015","journal-title":"Vaccine"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrm3738","article-title":"Synthetic biology in mammalian cells: Next generation research tools and therapeutics","volume":"15","author":"Lienert","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Silva-Pilipich, N., Beloki, U., Salaberry, L., and Smerdou, C. (2024). Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19. Vaccines, 12.","DOI":"10.3390\/vaccines12030318"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"ref_91","first-page":"389","article-title":"The vaccine supply chain: A call for resilience analytics to support COVID-19 vaccine production and distribution","volume":"2011","author":"Golan","year":"2020","journal-title":"Syst. Risk Resil."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Alizadeh, M., Amini-Khoei, H., Tahmasebian, S., Ghatrehsamani, M., Ghatreh Samani, K., Edalatpanah, Y., Rostampur, S., Salehi, M., Ghasemi-Dehnoo, M., and Azadegan-Dehkordi, F. (2022). Designing a novel multi\u2013epitope vaccine against Ebola virus using reverse vaccinology approach. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-11851-z"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/5\/524\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:32:57Z","timestamp":1760031177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/5\/524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":92,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["vaccines13050524"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13050524","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}